Oxaliplatin and its derivatives – An overview
Coordination Chemistry Reviews · 2023-12 · 497 · 215439
DOI: 10.1016/j.ccr.2023.215439 ↗Kurz gefasst
Fachartikel in der Zeitschrift Coordination Chemistry Reviews, 2023-12. Verfasst von Paul D. O'Dowd und 2 weiteren Autor:innen. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 340 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Science Foundation Ireland, European Regional Development Fund, Synthesis and Solid State Pharmaceutical Centre.
Abstract (Originalsprache)
Oxaliplatin was the third Pt-based anticancer drug to be clinically used worldwide. It exhibits a broad spectrum of anticancer activity and was the first to be approved for the treatment of colorectal cancer. Significantly oxaliplatin can induce immunogenic cell death and cytotoxicity via nucleolar stress in addition to established Pt(II) DNA damage responses. In this review, we describe oxaliplatin’s discovery, its properties and how it is administered as an anticancer agent. We provide an account of the current understanding of its mechanisms of action and resistance, which is essential background information for any medicinal inorganic chemist interested in designing and developing oxaliplatin derivatives, or indeed novel classes of Pt-based drugs. Furthermore we provide key examples of recent strategies employed to enhance oxaliplatin’s ability to overcome resistance, improve its specificity for cancer cells and improve Pt accumulation at the sites of tumors. In doing so we cover recent examples of (i) Pt(II) oxaliplatin derivatives, (ii) functionalised Pt(IV) oxaliplatin derivatives, (iii) photoactivatable oxaliplatin derivatives, (iv) oxaliplatin probes and (v) delivery platforms to enhance oxaliplatin accumulation. Oxaliplatin is certainly a unique member of the Pt-based anticancer class of chemotherapeutics. Continued research is required to improve our understanding of this important anticancer drug and to develop new classes of more effective selectively delivered analogues that overcome Pt resistance.
Förderung
- Science Foundation Ireland
- European Regional Development Fund
- Synthesis and Solid State Pharmaceutical Centre
Zitieren
APA
O'Dowd, P. D., Sutcliffe, D. F., & Griffith, D. M. (2023). Oxaliplatin and its derivatives – An overview. Coordination Chemistry Reviews, 497, 215439. https://doi.org/10.1016/j.ccr.2023.215439
Vancouver
O'Dowd PD, Sutcliffe DF, Griffith DM. Oxaliplatin and its derivatives – An overview. Coordination Chemistry Reviews. 2023;497:215439. doi:10.1016/j.ccr.2023.215439
BibTeX
@article{ODowd2023,
author = {O'Dowd, Paul D. and Sutcliffe, Darragh F. and Griffith, Darren M.},
title = {Oxaliplatin and its derivatives – An overview},
journal = {Coordination Chemistry Reviews},
year = {2023},
volume = {497},
pages = {215439},
doi = {10.1016/j.ccr.2023.215439}
}
EUVIMED